Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The dietary supplement inosine, which the body converts to urate, safely raises blood urate levels in people with early stage Parkinson's disease (PD), according to a new study. The result paves the way for testing inosine as a potential treatment for slowing PD progression. The research appears in the December 23 issue of JAMA Neurology.
Earlier studies have suggested that PD progresses more slowly in people whose natural levels of uric acid (urate), are higher than average. Research with laboratory mice has shown urate to have neuroprotective properties, meaning it has shown potential to protect the brain cells lost in Parkinson's. Too much urate, however, can cause gout and kidney stones.
The new research, called the Safety of Urate Elevation in PD (SURE-PD) study, aimed to test how well inosine raised levels of urate in blood and cerebrospinal fluid (the body fluid that bathes the brain), and whether higher levels were safe. Between 2009 and 2011, researchers at 17 clinical study sites recruited 75 people with early stage PD to participate in the study. Study participants were on average 62 years old, had been diagnosed with PD for about a year, and had blood urate levels less than 6 mg/dL. None were taking levodopa, but some used MAO-B inhibitors (selegiline or rasagiline).
Every day, for up to 24 months, one-third of the study participants took placebo capsules, one-third took enough inosine to raise urate levels to 6.1 to 7.0 mg/dL, and one-third took enough inosine to raise urate levels to 7.1 to 8.0 mg/dL. The researchers regularly tested participants' urate levels. The study was double-blinded, meaning that neither study participants nor the health care workers they interacted with knew who received inosine and who received placebo.
What Does It Mean?
Epidemiological studies have shown that higher urate levels are associated with better prognosis in PD. However, it was unknown whether urate levels can be safely elevated in people with PD and whether this elevation would improve PD prognosis. In this study, scientists have shown that urate levels can be relatively safely elevated by taking the supplemental compound inosine. Taken together with previous findings, the results of this study support testing inosine in a clinical trial to investigate its ability to slow the progression of PD.
Much research points to oxidative stress as one of the molecular mechanisms that underlies PD. Urate is a potent antioxidant, which provides a rationale for looking into its potential benefits, although the details of how it may work in humans are not known.
The study authors emphasize that, although elevated from the start of the research, participants' urate levels were still within the normal range. They also caution that raising urate levels by taking inosine supplements or through diet can result in gout and kidney stones.
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease - A Randomized Clinical Trial, The Parkinson Study Group SURE-PD Investigators, JAMA Neurol. Published online December 23, 2013. doi:10.1001/jamaneurol.2013.5528
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Parkinson's Disease category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Foundation, Parkinson's Disease. "Paving the way to test inosine's ability to slow Parkinson's progression." Medical News Today. MediLexicon, Intl., 30 Dec. 2013. Web.
11 Mar. 2014. <http://www.medicalnewstoday.com/releases/270649>
Foundation, P. (2013, December 30). "Paving the way to test inosine's ability to slow Parkinson's progression." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270649.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.